Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Genelux Corp

GNLX ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$2.74

▲ +4.18%

Market Cap $123.97M · Vol 97.06K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$123.97M

Micro Cap

Div Yield

N/A

EPS Growth

+5.23%

YoY

RSI (14)

43.23

Momentum

Beta

0.54

vs Market

52W High

$8.54

67.90% below

52W Low

$2.29

19.65% above

Volume

97.06K

Avg 55.91K

P/B

14.24

Price-to-book

ROE

N/A

Return on equity

Free Float

86.89%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Genelux Corp (GNLX) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does GNLX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+3.01%

-5.19%

-9.87%

+4.98%

YTD

-37.16%

-19.65%

-88.70%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$8.00K
Net Income	$-32,145,000.00
Revenue Growth (YoY)	N/A
Gross Margin	100.00%
Operating Margin	-415,175.00%
Net Profit Margin	-401,812.50%
ROE	N/A
ROA · ROIC	-119.62% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	20,261.21
P/B	14.24
P/FCF	N/A
EPS Growth	+5.23%
Outstanding Shares	45.25M

Technical Indicators

50-Day SMA	$2.89
200-Day SMA	$3.36
RSI (14)	43.23
Beta	0.54
52-Week High	$8.54
52-Week Low	$2.29

Volume Today	97.06K
Avg Daily Volume (30D)	55.91K
Relative Volume	1.74x
Volatility (10D)	80.21
Volatility (30D)	57.28
Free Float	86.89%

Analyst Consensus

BUY

Current Price $2.74

Mean Target $17.50

52W Low$2.29 52W High$8.54

Current

Target

$2.29 $8.54

Current Analyst target

+538.69% upside potential · 6 analysts

Identifiers

ExchangeNasdaq

FIGIBBG0044BNBY5

ISINUS36870H1032

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 10, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Genelux Corporation is a late clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its clinical and preclinical product candidates are intended to selectively kill tumor cells and induce a robust immune response against a patient’s tumor neoantigens. Its product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable deoxyribonucleic acid (DNA) virus with a large engineering capacity. Olvi-Vec is developed for the treatment of multiple cancers based on the results of preclinical studies that suggest Olvi-Vec has the potential to infect and directly kill a wide range of tumor cell types in vitro and in vivo and produce an anti-tumor immune response. Its portfolio also include oncolytic vaccinia immunotherapy clinical candidates.